Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Paraganglioma × Sunitinib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1 CNS 1

Conditions

Carcinoma, Renal Cell 50 Neoplasm Metastasis 19 Kidney Neoplasms 18 Breast Neoplasms 14 Carcinoma, Non-Small-Cell Lung 13 Neoplasms 11 Urinary Bladder Neoplasms 10 Prostatic Neoplasms 8 Lung Neoplasms 7 Glioblastoma 6 Gastrointestinal Stromal Tumors 6 Colorectal Neoplasms 6 Brain Neoplasms 6 Small Cell Lung Carcinoma 5 Ovarian Neoplasms 5 Neuroendocrine Tumors 5 Melanoma 5 Carcinoma 5 Uveal Melanoma 4 Thyroid Neoplasms 4 Thymoma 4 Sarcoma 4 Recurrence 4 Pancreatic Neoplasms 4 Multiple Myeloma 4 Liver Neoplasms 4 Esophageal Neoplasms 4 Adenocarcinoma 4 Urethral Neoplasms 3 Thyroid Cancer, Papillary 3

Interventions

lutetium Lu 177 dotatate 5 Temozolomide 3 Specimen Handling 3 olaparib 2 belzutifan 2 anlotinib 2 Magnetic Resonance Spectroscopy 2 3-Iodobenzylguanidine 2 177Lu-octreotide, DOTA(0)-Tyr(3)- 2 talazoparib 1 pazopanib 1 lanreotide 1 guadecitabine 1 gallium Ga 68 dotatate 1 copper dotatate CU-64 1 cabozantinib 1 atezolizumab 1 Sunitinib 1 Nivolumab 1 Lutetium-177 1 Lutetium 1 Ipilimumab 1 Fluorodeoxyglucose F18 1 Contrast Media 1 CTLA-4 Antigen 1 Biopsy 1 Axitinib 1 90Y-octreotate, DOTA(0)-Tyr(3)-Thr(8)- 1 3-fluorobenzylguanidine 1 3-(8-amino-1-(2-phenylquinolin-7-yl)imidazo(1,5-a)pyrazin-3-yl)-1-methylcyclobutanol 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01371201 2022-08-04

FIRSTMAPPP

Gustave Roussy, Cancer Campus, Grand Paris

Phase 2 Completed

Paraganglioma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡